Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 2/20 | 0.66 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.66 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.55 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.55 |
| ▸ | MIF | P14174 | 1/20 | 0.55 |
| ▸ | HTR2A | P28223 | 1/20 | 0.55 |
| ▸ | HTR2B | P41595 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 5/20 | 0.49 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.49 |
| ▸ | GALR3 | O60755 | 1/20 | 0.49 |
| ▸ | DRD1 | P21728 | 2/20 | 0.47 |
| ▸ | DRD3 | P35462 | 2/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.47 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.47 |
| ▸ | HTR1A | P08908 | 1/20 | 0.47 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.47 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.47 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9918287 | 1.00 | OPRM1 (0.66) | OPRM1SLC22A1ADRA1AADRB1MIF | |
| SCHEMBL5014485 | 0.90 | OPRM1 (0.67) | OPRM1SLC22A1ADRA1AADRB1MIF | |
| SCHEMBL5177521 | 0.90 | OPRM1 (0.67) | OPRM1SLC22A1ADRA1AADRB1MIF | |
| SCHEMBL15471672 | 0.87 | OPRM1 (0.73) | OPRM1SLC22A1ADRA1AADRB1MIF | |
| SCHEMBL16871402 | 0.87 | OPRM1 (0.73) | OPRM1SLC22A1ADRA1AADRB1MIF | |
| SCHEMBL13082446 | 0.85 | ADRB1 (0.55) | OPRM1SLC22A1ADRA1AADRB1MIF | |
| SCHEMBL12967704 | 0.83 | ADRB1 (0.53) | OPRM1SLC22A1ADRA1AADRB1MIF | |
| SCHEMBL725882 | 0.82 | OPRM1 (0.68) | OPRM1SLC22A1ADRA1AADRB1MIF | |
| SCHEMBL18371747 | 0.82 | OPRM1 (0.59) | OPRM1SLC22A1ADRA1AADRB1MIF | |
| SCHEMBL15471651 | 0.82 | OPRM1 (0.68) | OPRM1SLC22A1ADRA1AADRB1MIF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10647744-B2 | Tripeptide epoxy ketone protease inhibitors | ONYX THERAPEUTICS, INC. (US) | 2020-05-12 | — | — | US | disclosed |
| US-20180072677-A1 | Peptidomimetics and Methods of Using the Same | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2018-03-15 | — | — | US | disclosed |
| EP-2519100-B1 | INTERMEDIATE COMPOUNDS AND PROCESSES FOR THE PREPARATION OF TAPENTADOL AND RELATED COMPOUNDS | MAPI PHARMA LTD (IL) | 2017-03-15 | — | — | EP | disclosed |
| US-20120149662-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10647744-B2 | Tripeptide epoxy ketone protease inhibitors | PREP, CTRL, ENPEP | OPRM1 4515/4885SLC22A1 3632/4885ADRA1A 4459/4885 |
| US-20120149662-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | JAK2, JAK1, JAK3 | OPRM1 4238/4885SLC22A1 3944/4885ADRA1A 4637/4885 |
| US-20180072677-A1 | Peptidomimetics and Methods of Using the Same | OPRM1, OPRL1, OPRD1 | OPRM1 1/4885SLC22A1 1690/4885ADRA1A 117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.